2′-Behenoyl-Paclitaxel Conjugate Containing Lipid Nanoparticles for the Treatment of Metastatic Breast Cancer

Cancer Letters - Ireland
doi 10.1016/j.canlet.2012.08.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Trastuzumab-Containing Regimens for Metastatic Breast Cancer

Cochrane Database of Systematic Reviews
2014English

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Cancer
Cancer ResearchOncology
2010English

Choosing Treatment for Metastatic Breast Cancer.

BMJ
1982English

SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Vectors for Treatment of Metastatic Breast Cancer

2005English

MicroRNA-200c Delivered by Solid Lipid Nanoparticles Enhances the Effect of Paclitaxel on Breast Cancer Stem Cell

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2016English

Physicochemical Properties and Biocompatibility of a Polymer-Paclitaxel Conjugate for Cancer Treatment

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy